生物醫藥控股 BHVN 深 滬
等待開盤 03-26 09:30:00 美东时间
8.61
+0.220
+2.62%
華盛通- 最 高8.80
- 今 開8.53
- 成交量 181.84万股
- 最 低 8.47
- 昨 收 8.39
- 總市值 12.95亿
- 52周最高 24.06
- 市盈率 靜 --
- 換手率 1.21%
- 52周最低 7.48
- 委 比 -65.16%
- 總股本 1.50亿
- 歷史最高 152.56
- 量 比 0.65
- 振 幅 3.93%
- 歷史最低 7.10
- 每 手 1
- 風險率 4.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biohaven Completes Enrollment In Phase 2 Proof-Of-Concept Study Of Taldefgrobep Alfa For Obesity; Topline Data Expected In 2H 2026
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026.Taldefgrobep is a novel inhibitor of the
03-19 19:34
Biohaven completes enrollment in Phase 2 obesity trial of taldefgrobep alfa, with topline data due in 2H 2026
Biohaven completes enrollment in Phase 2 obesity trial of taldefgrobep alfa, with topline data due in 2H 2026 Biohaven reported completion of enrollment in a Phase 2 randomized, double-blind, placebo-controlled, dose-ranging study of taldefgrobep alfa as monotherapy in adults with overweight or obes
03-19 19:30
Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why
Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million private placement announcement.
03-19 15:11
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
TD Cowen Maintains Buy on Biohaven, Raises Price Target to $30
TD Cowen analyst Tyler Van Buren maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $15 to $30.
03-11 22:28
What's Going On With Biohaven Stock On Monday?
Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong seizure reduction results.
03-09 23:47
股价盘前飙升34%！uniQure BV等公司因 FDA官员离职股价大涨！
（来源：invest wallstreet） uniQure BV (NASDAQ:QURE)股价周一飙升36%,此前有报道称美国食品药品监督管理局疫苗和基因治...
03-09 20:41
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $22 to $23.
03-03 23:36
